Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 11/20 | 0.69 |
| ▸ | HTR2C | P28335 | 5/20 | 0.64 |
| ▸ | HTR2A | P28223 | 2/20 | 0.64 |
| ▸ | HTR2B | P41595 | 2/20 | 0.64 |
| ▸ | MAOB | P27338 | 7/20 | 0.58 |
| ▸ | MAOA | P21397 | 6/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8233501 | 1.00 | KDM1A (0.69) | KDM1AHTR2CHTR2AHTR2BMAOB | |
| Hydrochloric Acid SCHEMBL4496679 | 0.98 | KDM1A (0.67) | KDM1AHTR2CHTR2AHTR2BMAOB | |
| Hydrochloric Acid SCHEMBL4496681 | 0.98 | KDM1A (0.67) | KDM1AHTR2CHTR2AHTR2BMAOB | |
| SCHEMBL22086329 | 0.82 | HTR2C (0.54) | KDM1AHTR2CHTR2AHTR2BMAOB | |
| SCHEMBL1524989 | 0.82 | KDM1A (1.00) | KDM1AMAOBMAOA | |
| SCHEMBL21840986 | 0.82 | KDM1A (1.00) | KDM1AMAOBMAOA | |
| SCHEMBL1524990 | 0.82 | KDM1A (1.00) | KDM1AMAOBMAOA | |
| SCHEMBL14880656 | 0.82 | KDM1A (1.00) | KDM1AMAOBMAOA | |
| SCHEMBL25066065 | 0.81 | KDM1A (0.55) | KDM1AHTR2CHTR2AHTR2BMAOB | |
| SCHEMBL12875675 | 0.81 | HTR2C (0.59) | KDM1AHTR2CHTR2AHTR2BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867226-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2018-11-14 | — | — | EP | claimed |
| US-9815819-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | claimed |
| EP-2867226-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2018-11-14 | — | — | EP | disclosed |
| US-9815819-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| US-20150141455-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | disclosed |
| EP-2867226-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | Novartis AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014002051-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |
| US-7425633-B2 | Pyrrolidine compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-09-16 | — | — | US | disclosed |
| US-7425633-B2 | Pyrrolidine compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-09-16 | — | — | US | disclosed |
| US-20070082932-A1 | Pyrrolidine compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2007-04-12 | — | — | US | disclosed |
| US-20070082932-A1 | Pyrrolidine compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141455-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | C5, C3AR1, C9 | KDM1A 4705/4885HTR2C 2131/4885HTR2A 1704/4885 |
| US-20070082932-A1 | Pyrrolidine compounds | DPP4, DPP7, DPP9 | KDM1A 1223/4885HTR2C 3931/4885HTR2A 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.